Ocumetics Technology is trading 5.9% up today at CA$0.45 after reporting positive six-month First-in-Human vision restoration data and progress toward Group Two surgeries.
- Clinical outcomes exceeded expectations, with all patients showing continuous vision improvements following the trial.
- Manufacturing of the company's redesigned accommodating lens has officially commenced, reinforcing confidence in its ophthalmic technology pipeline and clinical momentum.